Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease

BACKGROUND: Fabry disease results from deficient α-galactosidase A activity and globotriaosylceramide accumulation causing renal insufficiency, strokes, hypertrophic cardiomyopathy and early demise. We assessed the 10-year outcome of recombinant α-galactosidase A therapy. METHODS: The outcomes (seve...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Med Genet
Main Authors: Germain, Dominique P, Charrow, Joel, Desnick, Robert J, Guffon, Nathalie, Kempf, Judy, Lachmann, Robin H, Lemay, Roberta, Linthorst, Gabor E, Packman, Seymour, Scott, C Ronald, Waldek, Stephen, Warnock, David G, Weinreb, Neal J, Wilcox, William R
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2015
Assuntos:
Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4413801/
https://ncbi.nlm.nih.gov/pubmed/25795794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jmedgenet-2014-102797
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares